Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Allara Health

Two GLP-1 desks, one scoreboard. We put HealthRX and Allara Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 196 · Grade C

Allara Health

Visit Allara Health Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 66 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Allara Health a bad call — it's best for readers who want women with pcos or metabolic concerns wanting insurance-based branded glp-1 care. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
44
Supply Reliability
85
80
Transparency
83
64
Access Breadth
91
52
Clinical Oversight
89
89
Track Record
81
80
HealthRXBrief Score 86 · 66Allara Health

Price, coverage & the tracker

HealthRXAllara Health
Brief Score86/100 (B)66/100 (C)
Semaglutide$189/moFrom $149/mo (plus a separate fee, brand-name)
Tirzepatide$349/moNot disclosed
CoverageNot publicly listedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Allara Health: New to the tracker on 1 August 2026. The published line reads From $149/mo (plus a separate fee, brand-name) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.